GEP20043289B - Sustained Release Ranolazine Formulation - Google Patents

Sustained Release Ranolazine Formulation

Info

Publication number
GEP20043289B
GEP20043289B GEAP19995846A GEAP1999005846A GEP20043289B GE P20043289 B GEP20043289 B GE P20043289B GE AP19995846 A GEAP19995846 A GE AP19995846A GE AP1999005846 A GEAP1999005846 A GE AP1999005846A GE P20043289 B GEP20043289 B GE P20043289B
Authority
GE
Georgia
Prior art keywords
sustained release
release ranolazine
ranolazine formulation
ranolazine
formulation
Prior art date
Application number
GEAP19995846A
Inventor
Fiona Baker
John Richard Langridge
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of GEP20043289B publication Critical patent/GEP20043289B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Technical Result Providing therapeutic effectiveness of ranolazine concentration in blood plasma. 2. Essence A pharmaceutically dosed form comprises ranolazine and pH-dependent binder is used for treatment of arrhythmia, cardiac infarction, variant angina pectoris and exertional angina. 3. Field of Application Medicine.
GEAP19995846A 1998-09-10 1999-09-09 Sustained Release Ranolazine Formulation GEP20043289B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US32152298A 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
GEP20043289B true GEP20043289B (en) 2004-07-26

Family

ID=82020313

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19995846A GEP20043289B (en) 1998-09-10 1999-09-09 Sustained Release Ranolazine Formulation

Country Status (1)

Country Link
GE (1) GEP20043289B (en)

Similar Documents

Publication Publication Date Title
ATE309798T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CANNABIDIOL DERIVATIVES
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
MA24193A1 (en) PROCESSES FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE PEG-IFN ALPHA CONJUGATE, AND FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND THEIR USE
EE04238B1 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives, process for their preparation, pharmaceutical compositions containing said therapeutically active substances and use of said active compounds in therapy
MY118371A (en) Tetrahydrolipstatin containing compositions
NZ502280A (en) Combination therapy comprising atorvastatin and an antihypertensive agent
NO921875L (en) METAL PERIOD PREPARATIONS AND PROCEDURES FOR AA STIMULATED HAIR GROWTH
FI925342A0 (en) Process for the preparation of therapeutically active (+) - - (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol
HUP0000057A2 (en) Photochemotherapeutic compositions
AR016798A1 (en) USE OF A LACTOBACILLUS CEPA FOR THE PREPARATION OF A MEDICINAL PRODUCT
BRPI0108435B8 (en) formulation and use of low-dose entecavir
EE04997B1 (en) Pharmaceutical composition containing loteprednol and antihistamines, a medicament containing these agents, a process for the preparation of the medicament and use of a combination of these agents
HUP0003840A2 (en) Controlled released medical formulation
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
HUP0203682A2 (en) Method for administering a phosphodiesterase 4 inhibitor
NO943288L (en) Use of pentoxyphylline in the preparation of pharmaceutical preparations for the treatment of granulomatosis and fibrosis lung disease
DE59707988D1 (en) PHARMACEUTICAL COMBINATION PRODUCTS CONTAINING ERYTHROPOIETIN AND IRON PREPARATIONS
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
WO2001041747A3 (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer
GEP20043289B (en) Sustained Release Ranolazine Formulation
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
HUP9603327A2 (en) Topical pharmaceutical composition for applicating peptidelike compounds into the living organismus
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use